<code id='B863116BFB'></code><style id='B863116BFB'></style>
    • <acronym id='B863116BFB'></acronym>
      <center id='B863116BFB'><center id='B863116BFB'><tfoot id='B863116BFB'></tfoot></center><abbr id='B863116BFB'><dir id='B863116BFB'><tfoot id='B863116BFB'></tfoot><noframes id='B863116BFB'>

    • <optgroup id='B863116BFB'><strike id='B863116BFB'><sup id='B863116BFB'></sup></strike><code id='B863116BFB'></code></optgroup>
        1. <b id='B863116BFB'><label id='B863116BFB'><select id='B863116BFB'><dt id='B863116BFB'><span id='B863116BFB'></span></dt></select></label></b><u id='B863116BFB'></u>
          <i id='B863116BFB'><strike id='B863116BFB'><tt id='B863116BFB'><pre id='B863116BFB'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:97
          FDA stop sign
          Sarah Silbiger/Getty Images

          The Food and Drug Administration is cracking down on websites that claim to sell the underlying chemicals of popular diabetes and obesity drugs like Ozempic, Wegovy, and Zepbound, saying that the websites are selling unapproved and misbranded drug products.

          The regulator this week posted warning letters that it sent to two websites, Synthetix Inc. DBA Helix Chemical Supply and US Chem Labs. Though those websites say their chemicals are “for research use” and “not for human consumption,” the FDA said it found evidence on their pages showing that their products are indeed intended for human use, such as information about dosing and claims about the clinical benefits of the products.

          advertisement

          The two websites did not immediately respond to requests for comment. The FDA said they have 15 working days to respond and detail the steps they’ve taken to address any violations.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Medicare eyes cuts to doctors, raises to outpatient clinics in 2024
          Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

          APStockPhysiciansareinlinetoabsorbmoreMedicarecutsnextyear,whilehospitaloutpatientdepartmentsandsurg

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Grail faces three suits alleging harassment, retaliation

          GrailThreesalesexecutives,allofthemwomen,havefiledsuitagainstGrail,acancerdiagnosticscompany,allegin